Metastatic Breast Cancer, Triple Negative Breast Cancer Terminated Phase 2 Trials for Bevacizumab (DB00112)

Also known as: Metastatic Triple-negative Breast Cancer / Metastatic Triple Negative Breast Cancer / Triple-negative Metastatic Breast Cancer / Triple Negative Metastatic Breast Cancer

IndicationStatusPhase
DBCOND0074793 (Metastatic Breast Cancer, Triple Negative Breast Cancer)Terminated2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01069796Bevacizumab + Paclitaxel + Capecitabine in Triple Negative Metastatic Breast CancerTreatment